Sage Therapeutics has seen another clinical trial go up in smoke. The biotech called time on its plans to develop dalzanemdor in Alzheimer’s disease after seeing midphase data, adding to an earlier ...
On Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with ...
Experts believe they’ve identified a chemical compound in certain herbs that could help mitigate or prevent Alzheimer’s disease — but before anyone makes a run for the spice rack, there are a few ...
Oct 8 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal ...
Hosted on MSN
From the kitchen to clinic: Sage and rosemary show promise in the fight against Alzheimer’s
Alzheimer's is still one of the most debilitating neurodegenerative diseases, which affects millions across the globe and imposes a gigantic burden on families and healthcare systems. Although some ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled study to ...
Sage Therapeutics Inc.’s stock tumbled 5% Tuesday, after the company said it would cease development of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease due to a ...
Imagine a common sprig of rosemary or sage gracing your roast chicken! Now, imagine that this modest herb may harbor a powerful ally in the fight against Alzheimer’s. Yes, that’s right. Recent ...
A free Alzheimer's workshop will be held at The Ohio State University at Marion on Wednesday, May 28. Dr. Douglas Scharre, director of The Ohio State University Center of Cognitive and Memory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results